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1. Introduction 
Thyroid dysfunction is a common condition mainly affecting women, with a male to female 
ratio of around 1:10. An organ-specific autoimmune response is the underlying cause in the 
majority and susceptibility to thyroid autoimmunity is believed to be influenced by an 
interaction between genetic predisposition and environmental factors, in addition to 
endogenous factors such as age and sex (Vanderpump 1995).  
Autoimmune hyperthyroidism, or Graves’ disease (GD), affects around 2% of the female 
population and is characterised by the presence of thyroid stimulating antibodies (TSAb), 
which mimic the action of thyroid stimulating hormone (TSH), resulting in uncontrolled 
thyroid hormone production. TSAb also contribute to extra-thyroidal manifestation of the 
disease, including thyroid eye disease (TED), although the exact mechanistic pathways are not 
entirely clear. At the other end of the spectrum, autoimmune hypothyroidism (AH) affects up 
to 5% of women and is characterised by the presence of thyroid peroxidase (TPO). These 
antibodies do not seem to have a direct functional role but are implicated in perpetuating the 
intrathyroidal inflammation and tissue destruction (Ajjan & Weetman 2008).  
In this Chapter, we discuss the various therapies used in hyper- and hypothyroidism, and 
address management of special cases. 
2. Aetiology of hyperthyroidism 
GD is by far the commonest cause of hyperthyroidism accounting for around 80% of cases 
(Weetman 2000). It is frequently seen in multiple family members indicating a genetic 
predisposition, commonly seen in organ-specific autoimmune conditions.  
The second commonest cause is a solitary toxic nodule or multinodular goitre accounting 
for 15-20% of cases (Orgiazzi & Mornex1990). Toxic multinodular goitres tend to occur 
insidiously in elderly patients with a longstanding nodular goitre. Toxic adenomas result 
from benign monoclonal proliferation producing a single autonomously functioning nodule, 
typically greater than 2.5cm in diameter. Goitres of any nature are more prevalent in iodine 
deficient areas and are more common in females (Reinwein et al 1988). 
There are other rare causes for hyperthyroidism, which should be kept in mind when 
assessing the patient and these are summarised in Table 1.  
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Cause of hyperthyroidism Frequency and aetiology Diagnosis 
Graves’ disease 
99%, thyroid stimulating 
antibodies 
Clinical examination 
(Smooth goitre, 
extrathyroidal complications) 
Thyroid autoantibodies 
Thyroid uptake scan in 
difficult cases 
   
Toxic nodule or toxic 
multinodular goitre 
15%, activating mutations in 
TSH receptor and Gs protein 
Clinical examination 
Thyroid uptake scan 
   
Thyroiditis 
3%, autoimmune, viral or drug-
related (amiodarone) 
Clinical examination 
Thyroid uptake scan 
ESR 
   
TSH-secreting tumour <1% 
Raised TSH and thyroid 
hormones 
Pituitary imaging 
   
Exogenous thyroid 
hormone administration 
Variable, excess ingestion of 
thyroid hormones 
Clinical assessment 
   
Hyperemesis gravidarum 
Choriocarcinoma 
Rare, raised hCG 
Clinical assessment 
Absence of thyroid 
autoimmunity 
Known pregnancy 
Imaging of the pelvis 
   
Struma ovarii 
Rare, ectopic ovarian thyroid 
tissue 
Clinical assessment 
Thyroid/pelvic uptake scan 
Imaging of the pelvis 
   
Thyroid hormone 
resistance 
Rare, pituitary resistance to 
thyroid hormones 
Clinical assessment 
Family history 
 
 
Table 1. Hyperthyroidism: aetiology and diagnosis. 
2.1 Diagnosis of hyperthyroidism 
Main symptoms and signs of hyperthyroidism are summarised in Table 2. Careful history 
and examination will typically point towards a diagnosis of hyperthyroidism and its 
underlying cause. Biochemical confirmation is required and enables the clinician to monitor 
response to treatment. Levels of thyroid stimulating hormone (TSH) are suppressed 
(<0.03miu/l) together with elevated levels of circulating thyroid hormones, L-thyroxine (T4) 
and/or L-triidothyronine (T3). Measurement of TSH and free T4 (FT4) is usually sufficient to 
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confirm a diagnosis of thyrotoxicosis, but FT3 levels should be measured when TSH levels 
are suppressed with normal FT4 levels as roughly 5% of all cases may only have elevated 
levels of T3 (Singer et al 1995). 
The diagnosis of GD is usually based on clinical and biochemical thyrotoxicosis in the 
presence of a smooth goitre with or without extrathyroidal manifestation of the disease. In 
some cases, the cause of hyperthyroidism is unclear and additional biochemical and/or 
imaging tests may be needed.  
The presence of thyroid autoantibodies supports the diagnosis of thyroid autoimmunity. 
Antibodies (Ab) against TPO are frequently checked in clinical practice, although these are 
only detected in 80% of individuals with GD (Ajjan & Weetman 2008). Antibodies against 
thyroid stimulating hormone receptor (TSHR) are detected in 95-99% of patients with GD 
(depending on the sensitivity of the test used) and therefore these are more informative than 
TPO-Ab in cases of uncertain aetiology (Ajjan&Weetman 2008; Matthews & Syed 2011). 
Radioisotope uptake scans using 99mtechnetium or 131iodine, will show an increase in 
uptake and a diffusely enlarged thyroid in GD. Toxic MNG will show multiple nodules with 
increased uptake. A solitary nodule with increased uptake and suppressed function in the 
remaining, normal tissue is seen in a toxic adenoma (Cooper 2003). All forms of thyroiditis 
can be differentiated by low or absent uptake. 
Symptoms Frequency 
Nervousness, irritability, heat intolerance, palpitation  >90% 
Weight loss, increased appetite, fatigue, loose stool >80% 
Eye symptoms (TED) >50% 
Menstrual irregularities, insomnia, polyuria >25% 
Signs Frequency 
Hyperkinetic behaviour, fast speech, tachycardia, tremor, goitre, 
tachycardia or atrial fibrillation, moist skin 
>90% 
Thrill/bruit over the thyroid >70% 
Eye signs (in GD), thinning of hair, hyperreflexia 50% 
Pretibial myxoedema and acropachy (in GD), onycholysis  5% 
Table 2. Main symptoms and signs in Graves’ disease. TED: thyroid eye disease, GD: 
Graves’ disease. 
2.2 Management of hyperthyroidism 
There are three main treatment modalities for hyperthyroidism, which include medical 
therapy, radioactive iodine and surgery. In addition, supportive therapy is sometimes 
required to control symptoms. Treatment options for hyperthyroidism are summarised in 
Figure 1. 
2.2.1 Medical 
Control of hyperthyroidism. Anti thyroid drugs (ATD), known as thionamides, are commonly 
prescribed to control the excessive production of thyroid hormone and include carbimazole, 
its active metabolite methimazole and propylthiouracil (PTU). Use of these agents varies 
worldwide; methimazole and PTU are preferred in the USA, carbimazole is widely used 
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first line in the United Kingdom and Methimazole is preferred in the rest of Europe and 
Asia (Weetman 2000). Methimazole or Carbimazole is often preferred to PTU as it has a 
longer half life and is therefore given once a day whereas PTU needs to be taken 2 or 3 times 
a day (Franklyn 1994). They should generally be instituted in patients with a confirmed 
diagnosis of hyperthyroidism, but may not be necessary if definitive treatment is planned 
early and hyperthyroidism is mild (Weetman 2000). Thionamides can be used in the short 
term to induce euthyroidism prior to more definitive treatment such as radio-iodine or 
surgery or in the medium term in case of GD with the aim of inducing remission. Long term 
treatment is reserved for patients in whom definitive treatment is relatively contraindicated, 
such as elderly, frail patients  
T4 and T3 molecules are formed within the thyroid gland by the coupling of iodotyrosine 
residues, which in turn have been formed from the binding of iodine and tyrosine within 
thyroglobulin, an action catalysed by TPO (Cooper 2005). The thionamides act by 
inhibiting the formation and coupling of these iodotyrosine residues and thus reduce T4 
and T3 concentrations. Propylthiouracil also has the action of inhibiting the peripheral 
conversion of T4 to T3. 
Carbimazole is usually commenced at a dose of 20-40mg once a day, depending on the 
severity of thyrotoxicosis. Regular monitoring of TSH and T4 is required every 4-6 weeks 
and the initial dose can be titrated as the thyroid function normalises and the patient 
becomes euthyroid. A drop in the T4 to low-normal levels or below the normal range 
indicates that a reduction in dosage or addition of levothyroxine is needed. The former 
scenario constitutes the “titration regime”, whereas the latter is known as “block and replace 
regime”. In the titration regime, the smallest dose of anti-thyroid drug is used to maintain 
thyroid function within the normal range. The levels of T4 and T3 will begin to reduce 
within 2-4 weeks of treatment, however the TSH may remain suppressed for significantly 
longer and hence TSH alone should not be used to guide and monitor treatment (British 
Thyroid Association guidelines [BTA] 2006, Bahn 2011). 
If block and replace is used, which is usually reserved to individuals with GD, the patient 
is maintained on a high dose of carbimazole or propylthiouracil for 4-6 weeks and when 
the T4 levels fall to the normal range, Levothyroxine is commenced (usually 75-150 µg 
daily, according to patient weight) whilst continuing with the same dose of thionamide. 
Regular monitoring of TSH and T4 are required initially with alterations in the dose of 
thyroxine guided by T4 levels. Once established on a maintenance dose and TSH and T4 
levels have normalised, the doses are unlikely to vary and so less frequent testing is 
possible (e.g. 6 monthly). Block and replace regimes should not be used in pregnant 
women (detailed below). 
If thionamides are used to treat Graves’ disease they can usually be discontinued after a 
course of treatment, ranging from 6-18 months, with approximately 50% of patients 
remaining in remission thereafter (Hedley et al 1989, Maugendre et al 1999). In most centres, 
titration regime is administered for 18 months, whereas block and replace is usually given 
for 6 months only (Abraham et al 2005). There does not appear to be a difference in 
remission rates between titration and block and replace regimes (Abraham et al 2005, 
Reinwein at al 1993). Higher rates of relapse typically occur with severe biochemical 
thyrotoxicosis at diagnosis, a large goitre, extrathyroidal complications, high anti-TSHR 
titres and in men (Vitti et al 1997). Thyrotoxicosis caused by nodular goitres does not 
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undergo remission and generally requires a more definitive treatment once the initial 
thyrotoxicosis has been controlled. 
Management of hyperthyroidism
Medical  RAI Surgery
Control of hyperthyroidismControl of symptoms
ΒB, CCB
Caution: asthma (BB) 
Thionamides: Carbimazole, 
methimazole, propylthiouracil
Treatment can be given as 
titration or block & replace
Caution: AGRANULOCYTOSIS 
Rarely: potassium iodide,  
potassium perchlorate, lithium
Outcome
Remission of GD in 50% of cases after 6‐18 
months treatment
Discontinue once
euthyroid
Indicated for:
TMNG
GD (particularly 
relapsed disease)
Caution: pregnancy, 
TED, incontinence, 
breast feeding
Outcome
Euthyroid/hypothyroid
in 90% after 1st dose 
Indicated for:
CI to medical therapy
Relapsed GD & TED
Large disfiguring goitre
Suspicious thyroid nodules
Patient preference
Caution: laryngeal nerve
palsy, hypoparathyroidism
bleeding
Outcome
Hypothyroidism
Possible hypocalcaemia
(transient or permanent)
 
Fig. 1. Summary of the management of hyperthyroidism. BB: β-blockers, CCB: calcium 
channel blockers, GD: Graves’ disease, TMNG: toxic nodular goitre, TED: thyroid eye 
disease, CI: contraindication. 
Several side effects can be attributed to thionamide medication. Common adverse effects 
include nausea, gastrointestinal upset, headache, fever, rash, urticaria and arthralgia. Rarely, 
hair loss may occur as a result of carbimazole therapy, although this may also be a 
manifestation of thyrotoxicosis. More worrying but less frequent side effects include 
agranulocytosis, vasculitis, and hepatitis, with the latter being more of an issue with PTU 
(Cooper & Rivkees 2009). Agranulocytosis occurs in approximately 0.4-0.5% of cases. All 
patients are warned of this rare but serious side effect and asked to immediately report 
symptoms consistent with agranulocytosis such as severe sore throat, fever or mouth ulcers. 
Urgent full blood count is required in patients taking thionamide with such symptoms and 
treatment withheld until it is clear that white blood cells and neutrophil counts are normal. 
When such a complication develops, patients are admitted to hospital, given appropriate 
antibiotics and a haematology opinion is sought, particularly if they require granulocyte 
stimulating factor administration. Once a patient develops agranulocytosis to an antithyroid 
drug, it represents a contraindication to the use of other thionamides (Biswas 1991). 
However, in the presence of other adverse effects, swapping to another antithyroid 
medication is a possibility. For example, arthralgia induced by carbimazole does not 
necessarily occur with propylthiouracil treatment. 
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Supportive management. Some patients who present with significant thyrotoxic symptoms 
require supportive treatment whilst awaiting normalisation of thyroid hormone levels. 
Typically β-adrenergic blockers such as propranolol are used until thyroid function tests 
improve at which point they may be withdrawn (Franklyn 1994). Caution must be used in 
patients with a contra-indication such as heart failure and asthma. An alternative therapy 
would be a non-dihydropyridine calcium channel blockers such as diltiazem or verapamil  
Other medical therapies. Treatments such as potassium iodide, potassium perchlorate and 
lithium are less conventional, but possible treatment options, particularly when 
agranulocytosis develops secondary to antithyroid drug treatment. When given in large 
enough quantities, potassium iodide blocks the synthesis and release of thyroid hormones 
from a thyrotoxic gland and results in an accumulation of iodide within the gland. A 
significant reduction in thyroid hormones can be seen as quickly as 2 days following 
administration, and is typically reserved for preparing thyrotoxic patients, who are unable 
to tolerate thionamide medication, for surgery. However, this treatment can only be given 
for a short period of time as the patient eventually “escapes” from the inhibitory effect of 
iodine (Philippou 1992).  
Lithium acts by inhibiting the release of T4 & T3 and is generally used in similar 
circumstances to potassium iodide or in combination with a thionamide in patients who 
have needed recurrent doses of radioiodine as it is thought to help retention of I131 (Bal et al 
2002, Bogazzi et all 1999). Potassium perchlorate is generally reserved for use in type 1 
amiodarone induced thyrotoxicosis and requires similar monitoring to other anti-thyroid 
medication, with aplastic anaemia being the most serious side effect.  
2.2.2 Radioactive Iodine (RAI) 
Indications for RAI. This can be used as a primary treatment for hyperthyroidism or as a 
secondary option if anti-thyroid medication has failed to control hyperthyroidism. It is 
common practice for patients with GD to undergo a course of anti-thyroid medication 
initially. If this does not achieve long term euthyroidism, due to either the relapsing nature 
of the condition following withdrawal of ATD or treatment difficulties, then radioactive 
iodine is indicated as a definitive treatment due to long term morbidity and mortality 
associated with uncontrolled hyperthyroidism. Severe adverse events such as 
agranulocytosis and hepatic dysfunction caused by thionamides are also an indication for 
RAI (Royal College of Physicians [RCP] 2007). It is more commonly used in North America 
as a primary treatment in patients with GD (Solomon et al 1990), due to poor remission 
rates, and other factors including age, pre-existing medical conditions such as 
cardiovascular disease, availability of RAI and patient preference may influence this 
decision. RAI is recommended in patients with hyperthyroidism due to nodular goitres as 
antithyroid drugs do not result in long term cure of the disease. 
RAI is successful in achieving long-term euthyroidism or hypothyroidism in approximately 
90% of patients after a single dose of between 400-600MBq after 1 year (Regalbuto et al 
2009). A minority will require a second dose and very rarely a third treatment with RAI. 
Contraindications to RAI. Pregnancy and breastfeeding are absolute contraindications to RAI 
and pregnancy should be avoided for 6 months following treatment. Iodine is concentrated 
in milk and is able to cross the placenta, damaging the foetal thyroid. RAI should also be 
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avoided in patients who are unable to comply with the safety regulations after administration. 
Current treatment with amiodarone (or within the preceding 12 months) is another 
contraindication as this reduces the uptake of RAI into the thyroid, greatly reducing its efficacy 
as is suspicion of thyroid malignancy. Caution is needed in patients incontinent of urine, 
which represents a relative contraindication and insertion of a urinary catheter or urinary pads 
with appropriate disposal facilities are ways to circumvent the problem (RCP 2007). Another 
relative contraindication is individuals with active eye disease. If RAI treatment is necessary in 
TED patients then concurrent oral glucocorticoids are effective in reducing development or 
progression of TED (Bartalena 2011). Some centres, including ours, advocate starting block and 
replace one week after RAI for 6 months after which antithyroid drugs can be withdrawn and 
levothyroxine continued. This helps in avoiding fluctuation in thyroid function, which can be 
associated with worsening of TED (Tallstedt et al 1994). 
Precautions after RAI treatment. Most of the radioactivity is taken up by the thyroid, whilst 
some is excreted in urine and sweat. It is important that patients are able to comply with the 
necessary restrictions following RAI treatment to limit the radiation exposure of other 
members of the public. These include limiting close contact (less than 1m) with people, 
especially children under 3 years of age and pregnant women. The exact duration of the 
limitations will vary depending on the dose received, and can be up to 28 days (RCP 2007). 
Patients should be instructed to flush the toilet twice after passing urine and to wash their 
hands carefully. They should not share towels or face cloths and ensure that cutlery is 
thoroughly cleaned. Following RAI patients should be issued with a card outlining the 
details of their treatment and should carry this for 4 weeks or up to 6 months if they are 
travelling by plane as some airport security devices are able to detect levels of radioactivity 
this long after RAI (RCP 2007). 
Follow up and monitoring. Careful follow up after RAI is essential to detect alterations in 
thyroid status. Patients treated with ATD and who are biochemically euthyroid prior to 
RAI are unlikely to require subsequent ATD unless the risk of recurrent hyperthyroidism 
is deemed unacceptable such as in the elderly or those with cardiovascular co-morbidity 
(RCP 2007). Patients should be warned that there is a risk of an increase in hyperthyroid 
symptoms in the first 1-2 weeks after treatment which often respond to β-blockers. 
Thyroid function tests (TFT’s) should be performed around 6 weeks after RAI. 
Hypothyroidism within the first 6 months of RAI may be transient and thyroid 
replacement medication should only be commenced if there is a continual rise in TSH 
levels and falling freeT4 levels Aizawa et al 1997). If patients require re-commencement of 
ATD following RAI this should be gradually withdrawn over 3 to 5 months. If a patient 
remains euthyroid 6 weeks post RAI then further thyroid function tests should be 
performed at 12 weeks, 6, 9 and 12 months. In those who remain hyperthyroid 6 months 
post RAI, a second dose should be considered (RCP 2007). Annual TFT’s are subsequently 
required to monitor for late onset hypo-, or hyperthyroidism (BTA 2006). 
2.2.3 Surgery 
Patient selection. Thyroid surgery, in various guises, has been performed since the 1860’s as a 
treatment of goitres (Sawyers 1972). In the modern age there are a number of indications for 
thyroidectomy; relapse of GD following a course of ATD is one and patients who are unable 
to undergo RAI, i.e., pregnant women, those with small children who are unable to comply 
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with restrictions, and those with severe ophthalmopathy can be offered surgery as are those 
who decline RAI. Similarly, patients who are hyperthyroid due to nodular goitre may be 
offered surgery as a definitive treatment due to the same reasons. Other indications include 
thyroid malignancy or uncertainty regarding thyroid malignancy and to alleviate 
compressive or respiratory symptoms due to large goitres (BTA 2006). Another indication 
for surgery is a cold nodule in a patient with GD, due to the relatively high risk of 
malignancy in such nodules (Abraham-Nordling et al 2005). 
Preparation of patient for surgery. Euthyroid patients undergoing thyroid surgery require no 
special preparation prior to surgery. If they have had previous thyroid or parathyroid surgery, 
cervical disc operations or have a hoarse voice then direct or indirect laryngoscopy is 
recommended to identify previous recurrent laryngeal nerve palsy (Moorthy et al 2011). 
Thyrotoxic patients should be rendered euthyroid with ATD prior to surgery. Lugol’s Iodine 
was used to be given pre-operatively, which along with reducing thyroid hormone secretion is 
also thought to reduce thyroid blood flow. However, this is now less common and provided 
the patient is euthyroid, such a treatment is not usually required (Feek et al 1980).  
Post-operative complication. With careful pre-operative preparation and meticulous surgical 
technique, mortality from thyroid surgery should be <1% and similar to that of general 
anaesthesia alone (Weetman 2000). Complications do occur to varying degree and include 
thyroid storm, wound haemorrhage, hypoparathyroidism and recurrent laryngeal nerve 
injury. The incidence of thyroid storm as a result of thyroid surgery is now very low due to 
improved pre-operative treatment with ATD and post-operative management. Wound 
haemorrhage although rare, (occurring <1%) can be very serious and life threatening 
especially if there has been arterial bleeding causing tracheal compression. Any sign of 
wound haemorrhage causing respiratory compromise requires urgent intervention 
Schwartz et al 1998). The occurrence of hypoparathyroidism post-operatively can be either 
permanent or temporary and is rarely due to mistaken removal of all four parathyroid 
glands, but rather interruption to their blood supply (Pattou et al 1998). In the hands of 
experienced surgeons performing a total thyroidectomy, the risk is thought to be between 0-
3% (Schüssler-Fiorenza et al 2006). New techniques such as auto transplantation of 
parathyroid glands during surgery are effective at reducing these rates further (Testini et al 
2007). Injury to the recurrent laryngeal nerve is also thought to be around 1-2% and is also 
higher when surgery is performed for thyroid malignancy. Some return of function to the 
vocal cords can be expected within the first few months and possibly up to 12 months. 
Beyond this time it is likely that injury will be permanent.  
2.3 Special cases of hyperthyroidism 
2.3.1 Amiodarone induced thyrotoxicosis 
Treatment of amiodarone induced thyrotoxicosis (AIT) can be challenging, due in most part 
to the degree of overlap between type1 and type 2 AIT. The first step in the treatment of 
either case is to discontinue amiodarone if it is safe to do so, for which a cardiology opinion 
is usually sought. The attending physician attempt to distinguish whether the patient has 
type 1 or type 2 AIT (summarised in Table 2). Type 1 AIT is due to increased production of 
thyroid hormones, and so treatment with a thionamide should result in lowering of thyroid 
hormone levels. Occasionally potassium perchlorate can be added or substituted if there is 
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no response. If successful the dose of thionamide is tapered and the thyroid function tests 
are monitored. If there is little to no response from first line treatment for type 1 AIT, this 
may raise the possibility that type 2 AIT is the predominant aetiology. Type 2 AIT is more of 
an inflammatory response to the drug itself leading to an increase in release of thyroid 
hormone rather than excessive production. Main treatment involves glucocorticoids, usually 
prednisolone at a dose of 0.5-1.0 mg/kg/day which is tapered over several months 
according to response. If hyperthyroidism persists despite these measures, in both type 1 
and 2 AIT, then referral for thyroidectomy should be considered as RAI is unlikely to be of 
benefit due to reduced uptake secondary to amiodarone therapy. In clinical practice, it may 
be difficult to differentiate between type 1 and type 2 AIT, and sometimes both may occur 
together. Therefore, a pragmatic approach is frequently adopted by treating for both types 
of AIT simultaneously using antithyroid drugs and steroids. 
2.3.2 Thyroid storm 
Although thyroid storm is becoming increasingly less common due to improved diagnosis 
and treatment of hyperthyroidism, it remains a potentially life threatening emergency that 
requires urgent attention in an intensive care setting. Early supportive measures are 
important including fluid resuscitation, correcting electrolyte imbalances, supplemental 
oxygen, active cooling, and sedation if delirium is difficult to manage. Other treatments are 
based on clinical findings, such as broad spectrum intravenous antibiotics if infection is 
suspected and treating dysrhythmia or heart failure. More focused therapy includes ATD 
and typically PTU is preferred as it helps to lower T3 levels quicker that carbimazole due to 
its added effect of preventing peripheral conversion of T4 to T3 (Cooper & Rivkees 2009). 
PTU is given 6 hourly initially and usually oral administration is sufficient. Nasogastric tube 
may be required in individuals too ill to swallow and the drug can be administered 
intravenously if there are concerns over drug absorption. Unless contraindicated, 
propranolol is used to settle tachycardia and anxiety. Once ATD have been instituted, 
potassium iodide can be added, usually 1 hour after ATD and continued at a dose of 100 mg 
every 12 hours. The use of glucocorticoids is generally accepted, especially if there is a 
suspicion of concomitant adrenal insufficiency and may have the additional benefit of 
lowering T3 levels by preventing peripheral conversion of T4 to T3 (Bahn 2011). In extreme 
circumstances if there has not been a satisfactory response to treatment, procedures such as 
dialysis and plasma exchange can reduce levels of thyroid hormone, but in practice are very 
rarely required (Alfadhi & Gianoukakis 2011). 
 Type 1 AIT Type 2 AIT 
FH of thyroid autoimmunity Possible Usually absent 
Goitre Yes No 
Thyroid antibodies Yes No 
Vascularity of thyroid gland 
assessed by ultrasound 
Increased Decreased 
Raised inflammatory markers 
(IL-6, CRP) 
No Yes 
Table 2. Differentiation of type1 and type 2 amiodarone-induced thyrotoxicosis (AIT). FH: 
family history, IL: interleukin, CRP: C-reactive protein. 
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2.3.3 Pregnancy 
Patients who are receiving treatment with ATD should receive pre-conceptual advice with a 
view to optimal preparation prior to pregnancy. This includes ensuring they are euthyroid 
prior to conception and altering medication to PTU which is felt to be superior to 
carbimazole during pregnancy, especially in the first trimester due to reduced incident of 
aplasia cutis (Bowman et al 2011). Current evidence suggests that following organogenesis, 
carbimazole or methimazole should be re-introduced due to a possible increased risk of 
hepatitis with PTU (Lazarus 2011). Those on a block and replace regime should also be 
swapped to PTU alone as thionamides will cross the placenta but levothyroxine will not, 
thus increasing the risk of foetal goitre and hypothyroidism (Weetman 2000). Pregnant 
patients taking ATD should have frequent TFT’s throughout pregnancy (monthly) and the 
dose reduced to the lowest possible to maintain euthyroidism with T4 at the upper limit of 
the reference range (Lazarus 2011). Doses of ATD are reduced in the latter stages of 
pregnancy, and not infrequently stopped altogether as the condition undergoes remission. If 
hyperthyroidism is secondary to GD (or patient has had previous definitive treatment such 
as surgery or RAI) then TSH receptor antibodies should be measured as high titres can 
indicate intrauterine or neonatal thyrotoxicosis (Laurberg et al 1998). TSHR antibodies 
should not be checked in euthyroid patients previously treated with antithyroid drugs only. 
 
Management of special cases of hyperthyroidism
AIT Hyperthyroidism in pregnancy Thyroid storm
Type 2Type 1
Thionamides Glucocorticoids
Use both in unclear cases
Avoid block & replace
PTU preferred to carbimazole
Use smallest possible dose of PTU
Frequently monitor TFTs (remission 
of GD during pregnancy is common)
Surgery is reserved for severe cases 
(second trimester is safest)
Transfer patient to ICU setting
High dose antithyroid drugs 
(PTU preferred via NG tube)
Rarely: dialysis, plasma 
exchange
Supportive therapy
Steroid cover
Electrolytes/fluid
Sedation as necessary
Antibiotics
Cooling
Arrhythmias
Heart failure
 
Fig. 2. Management of special cases of hyperthyroidism. AIT: amiodarone induced 
thyrotoxicosis, GD: Graves’ disease, PTU: propylthiouracil, NG: nasogastric, TFT’s: thyroid 
function tests. ICU: intensive care unit. 
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All euthyroid patients who have previously received treatment for hyperthyroidism should 
have TFT’s checked in each trimester and importantly after delivery as there is an increased 
risk or recurrence post-partum. If surgery is required, due to allergy or adverse effect of 
ATD, it is safest to be performed in the second trimester. 
2.3.4 Subclinical hyperthyroidism 
Subclinical hyperthyroidism is defined as a low TSH level, which is below the reference range 
(<0.1-0.4 mU/l), in the presence of a normal T4 and T3 concentration. It has become an 
increasingly problematic clinical entity following the introduction of new and more sensitive 
serum TSH assays. Patients usually exhibit non-specific symptoms or have no symptoms at all. 
There remains much debate regarding the correct management of such patients, with a lack of 
firm evidence to support treatment at present. The ultimate goal of treating these patients early 
(with the same treatment options as discussed above) is to prevent progression to overt 
hyperthyroidism, to reduce the risk of developing atrial fibrillation (AF) and ostoeporotic 
fractures and reduce mortality (Vanderpump 2011). A serum TSH level of between 0.1 and 
0.4mU/l carries a very low risk of progression to overt hyperthyroidism, and so treatment 
need only be considered for those with a persistently suppressed TSH, especially in the 
presence of cardiovascular disease (Bahn 2011). Given the lack of supporting evidence 
advocating treatment, a pragmatic approach may be required, balancing the morbidity of 
hyperthyroid treatment against the risks of developing conditions such as AF, ostoeporotic 
fractures and overt hyperthyroidism (Vanderpump 2011). 
3. Aetiology of hypothyroidism 
The causes of hypothyroidism can be differentiated into primary thyroid failure or secondary 
central hypothyroidism caused by pituitary or hypothalamus failure. In clinical practice most 
cases are primary in nature, due to chronic autoimmune thyroiditis, which can be goitrous 
(Hashimotos thyroiditis) or non-goitrous (atrophic thyroiditis). Iatrogenic hypothyroidism is 
usually caused secondary to treatment of hyperthyroidism. Transient hypothyroidism may be 
seen following a post-partum thyroiditis or viral induced sub-acute thyroiditis as the thyroid 
begins recovery after a destructive phase in which stored thyroid hormone is released 
(Franklyn 1994). Causes of primary hypothyroidism are summarised in Table 3. 
3.1 Diagnosis of hypothyroidism 
Symptoms of hypothyroidism are numerous and are often also found in patients who are 
euthyroid, whilst some hypothyroid patients will complain of no symptoms at all. Clinical 
signs are also very variable, but if present give a strong suspicion of the disease. However 
the absence of signs cannot be relied upon to exclude a diagnosis. Thyroid function testing is 
vital to make a diagnosis and include the measurement of TSH and T4 levels. The presence 
of TSH >10mU/l and free T4 levels below the normal reference range indicate overt 
hypothyroidism and requires treatment with thyroid replacement hormone. Subclinical 
hypothyroidism is classified by TSH level above the normal reference range with normal T4. 
The majority of patients (>95%) with hypothyroidism due to thyroid autoimmunity have 
detectable TPO antibodies, which aid the diagnosis and help to differentiate from other 
causes of low thyroid hormone levels. The main clinical symptoms and signs of 
hypothyroidism are summarised in Table 4.  
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3.2 Management of hypothyroidism 
Treatment of individuals with hypothyroidism is relatively easy and consists of replacement 
with thyroid hormones. In frank hypothyroidism the decision to start treatment is 
straightforward but in subclinical disease, criteria to start treatment are more complex 
(detailed below). Management of hypothyroidism is summarised in Figure 3. 
 
Cause of hypothyroidism Aetiology Permanent? 
Primary Myxoedema Autoimmune Yes 
Hashimotos thyroiditis Autoimmune Yes 
Silent Thyroiditis Autoimmune No 
Postpartum thyroiditis Autoimmune 
No (30% may develop 
permanent hypothyroidism) 
Subacute thyroiditis Viral No 
Post-surgery Iatrogenic Yes 
Following RAI Iatrogenic Yes 
Drug induced Iatrogenic 
Reversible if drug 
discontinued 
Iodine deficiency or excess  Reversible 
Table 3. Causes of primary hypothyroidism. 
Management of hypothyroidism
Frank hypothyroidism
(Raised TSH, low  FT4)
Subclinical hypothyroidism
(TSH 4‐10 mIU/l & normal FT4)
Hypothyroid 
coma
Replace with LT4
No evidence for additional benefit 
of T3 replacement
Aim to normalise TSH 
Dose adjustment of LT4:
Pregnancy
Weight  gain/loss
Concomitant medications  (ferrous 
sulphate,  antacids…etc…)
LT4 therapy recommended:
Detectable TPOAb
Undetectable TPOAb but  patient 
symptomatic (trial of therapy)
Observe without treatment
Negative TPOAb and asymptomatic
Transfer patient to ICU setting
LT4 using NG tube or 
intravenously
No consensus regarding FT3 
therapy
Supportive therapy
Steroid cover
Electrolytes/fluid
Antibiotics
Warming
Respiratory support 
 
Fig. 3. Management of hypothyroidism. LT4: levothyroxine, TSH: thyroid stimulating 
hormone, TPOAb: thyroid peroxidise antibodies, ICU: intensive care unit. 
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3.2.1 Levothyroxine replacement 
In non-elderly individuals with no history of cardiovascular disease, levothyroxine can be 
commenced at a dose of 50-100mcg daily, otherwise low doses are started initially (25 mcg 
evey day or every other day). It is estimated that most individuals require roughly 1.4-1.6 
mcg/kg and so frequently doses will need to be titrated further, which can be done in 
increments of 25-50 mcg. Free T4 and TSH should be measured 8-12 weeks after 
commencing levothyroxine and after a change in dose. Until patients are on a stable dose 
of thyroxine, TSH and T4 should be checked together, after which annual check of TSH is 
sufficient. Controversy remains as to what value of TSH should be the target in 
hypothyroid patients treated with levothyroxine (Wartofsky & Dickey 2005). There does 
appear to be a lack of evidence supporting improved patient well being from maintaining 
TSH at the lower end of the reference range (BTA 2006), however many physicians 
continue to advocate this along with a lowering of the upper limit of the reference range 
for TSH to 2.5mu/L, given that >95% of euthyroid individuals have a TSH between 
0.4mU/l to 2.5 mU/L (Gursoy et al 2006). A pragmatic approach which our centre follows 
is to aim for a TSH in the lower reference range by adjustment of levothyroxine dose if a 
patient remains symptomatic. The suppression of TSH is certainly not recommended due 
to fears of osteoporosis and atrial fibrillation (BTA 2006).  
Assuming that a patient’s weight remains stable, with no alterations to their medication or 
change in co-morbidities, the dose of levothyroxine should in theory remain stable. There 
are several factors that require alterations in doses such as pregnancy, malabsorption and 
medication.  
Any state that produces intestinal malabsorption, such as coeliac disease, may lead to 
reduced uptake of thyroxine and hence a need to increase thyroxine dose. It is important 
to be weary of individuals who suddenly need an increase in thyroxine and who complain 
of gastrointestinal symptoms. Many medications can interfere with the absorption of 
thyroxine, such as ferrous sulphate, calcium carbonate, proton pump inhibitors, orlistat 
and cholestyramine (BTA 2006). Patients prescribed these medications should be advised 
to take them at least 2-4 hours apart from their thyroxine. In rare circumstances, TSH 
levels remain raised despite replacement therapy, usually due to compliance issues that 
the patient typically denies. Provided malabsorption is ruled out, a large dose of 
supervised levothyroxine replacement (1 mg/week) can be attempted, which fixes the 
problem in the majority (Grebe et al 1997).  
Symptoms Frequency 
Weakness, lethargy, slow speech and dry/coarse skin >90% 
Cold intolerance, facial oedema, coarse hair >80% 
Weight gain, constipation, hair loss, memory problems >60% 
Anorexia, impaired hearing, dyspnoea, menorrhagia >30% 
Emotional instability, chest pain, dysphagia 10% 
Signs Frequency 
Dry/coarse skin, facial oedema, thick tongue >80% 
Bradycardia, skin pallor, slow relaxing reflexes >65% 
Pericardial effusion 30% 
Ascites, pleural effusion, carpal tunnel syndrome <10% 
Table 4. Main symptoms and signs in autoimmune hypothyroidism 
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3.2.2 T3 replacement therapy 
The use of tri-iodothyronine, either alone or in addition to levothyroxine remains 
controversial (Escobar-Morreale et al 2005). LT-3 has a much shorter half life than T4 and so 
repeated doses are needed throughout the day, and this can also impair measurement of 
free T3. Measurement of free T4 when T3 is used alone is of no benefit, and similarly to T4 
treatment, the aim is for TSH within the normal range. There is currently no consistent 
evidence that combination therapy of T4 and T3 is superior to T4 treatment alone, and 
therefore this therapy is not generally advocated (BTA 2006). 
3.3 Special cases of hypothyroidism 
3.3.1 Myxoedema coma 
Myxoedema coma is a very rare complication of untreated hypothyroidism but is associated 
with significant mortality. Patients with severe long standing hypothyroidism suddenly 
become unable to maintain homeostasis, usually due to a precipitating event such as 
infection, heart failure, stroke, gastrointestinal bleeding or medications (mainly sedatives 
and analgesics). Prompt treatment with intravenous levothyroxine is required, initially with 
a loading dose, followed by smaller maintenance doses which can be given orally if the 
patient is able. No consensus exists as to whether T3 treatment should commence at the 
same time, or indeed if T3 alone is all that is required (Kwaku & Burman 2007). Caution is 
needed in the elderly, or those with cardiovascular disease due to increased risk of 
myocardial infarction and tachyarrhythmia. Concurrent use of intravenous glucocorticoids 
are usually required during initiation of thyroxine treatment due to the potential for 
evoking an adrenal crisis in the first few days as the hypothalamic-pituitary-adrenal axis is 
usually impaired in severe hypothyroidism. Other supportive measures include blankets to 
warm the patients slowly, cautious use of intravenous fluid to treat hypotension and a low 
threshold for broad spectrum antibiotics if infection is thought to be implicated. 
Consideration should be given early to intubation and mechanical ventilation if deemed 
appropriate, especially in a comatose patient.  
3.3.2 Pregnancy 
During pregnancy, it is common for thyroxine requirements to increase by roughly 50%, 
and it is essential therefore that all pregnant ladies on thyroxine are reviewed regularly 
during pregnancy so that dose alteration can be made. It is recommended that TSH is 
maintained at the lower end of the reference range during pregnancy, with the free T4 at 
the upper range of normal (Lazarus 2011). It is particularly important during the first 
trimester, before the foetal thyroid is formed, that normal maternal levels of T4 are 
maintained as they play a vital role in foetal neurological development (Williams 2008). 
TSH and T4 should be checked pre-conceptually, at antenatal booking, within each 
trimester and 4-6 weeks post-partum, at which point the dose of thyroxine can usually be 
reduced to pre-pregnancy levels (Lazarus 2011). 
3.3.3 Subclinical hypothyroidism 
This relatively common clinical scenario can cause management confusion. It is 
recommended that replacement therapy is started in those with TSH between 4 and 10 
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mIU/L and positive TPO antibodies as these individuals usually progress to overt 
hypothyroidism. In those with similar TSH levels, symptoms of hypothyroidism but 
negative TPOAb, a 6 months trial of replacement therapy is advocated with reassessment as 
to whether this therapy is needed. In asymptomatic individuals with negative TPOAb, 
simple observation with repeat TFT’s is probably all that is required (BTA 2006).  
4. Conclusion 
Thyroid dysfunction can represent a wide spectrum of disease and the consequences of 
under treatment are evident with the two extremes of thyroid storm and myxoedema coma. 
Treatment options of both hypo- and hyperthyroidism are generally well established but are 
not perfect and there remain several unanswered questions regarding both forms of 
management, such as the optimal range of TSH with thyroxine replacement, the duration of 
ATD for GD, and whether to treat subclinical disease. Ongoing research into such areas is 
likely to provide further insight into the conditions and new therapies. Even with an 
expansion of the evidence base, clinical experience is likely to remain an invaluable asset in 
many instances. Regardless of treatment, lifelong follow up is required to maintain 
euthyroidism.  
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